


### ESMO Preceptorship Programme

Brain Tumors - Athens - 28-29 Sep 2018



## BRAIN METS OF AMELANOTIC MELANOMA



### Brain Tumors – Athens – 28-29 Sep 2018

Disclosure of interest: none



### Brain Tumors – Athens – 28-29 Sep 2018

- First time I saw this patient in neurosurgery department in neurology clinical center when they invited oncologist as a consultant.
- Date of assesment: 05 Dec 2017
- Patient S, male, born in 1965, ECOG 1.
- Desease history:
- In september 2017 neurosurgeons removed tumor 3.0 cm in diameter of the left temporal area of the brain
- Histology: metastasis of amelanotic melanoma
- CT foundings: no evidence of other metastases
- Primary tumor not found



## Brain Tumors – Athens – 28-29 Sep 2018 DESEASE HISTORY

- After surgery patient was treated with Temozolomide alone without radiotherapy
- In November, the patient underwent a second surgery due to local relapse – metastasis of melanoma was removed
- In a month when I saw patient before third operation tumor grew from brain outside through skin sutures
- No evidence of other mets or primary tumor



# Brain Tumors – Athens – 28-29 Sep 2018 DESEASE HISTORY

- After third surgery analysis for BRAF-mutation was performed
- BRAF V600 positive
- Day before starting therapy with vemurafenib hole body CT was done 24 Dec 2017
- CT revealed new local relapse and two Mets in right hemisphere 23 and 18 mm in diameter



# Brain Tumors – Athens – 28-29 Sep 2018 DESEASE HISTORY

- 25 Dec 2018 patient started therapy with vemurafenib
- Control CT on 21 Jan 2018 revealed only a postsurgery changes in left temporal lobe and no evidence of metastasis
- Due to financial reason patient has stopped the therapy on 26 Feb 2018
- Few times patient did control CT and the last one was done 19 Jun 2018 - still without sings of progression



### Brain Tumors – Athens – 28-29 Sep 2018

• What is the minimal duration of immunotherapy for melanoma with brain metastasis?





### ESMO Preceptorship Programme

